alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# L_2014310EN.01003901.xml

| 30.10.2014 | EN | Official Journal of the European Union | L 310/39 |
| --- | --- | --- | --- |

30.10.2014

EN

Official Journal of the European Union

L 310/39

---

DECISION OF THE EEA JOINT COMMITTEE

No 86/2014

of 16 May 2014

amending Annex II (Technical regulations, standards, testing and certification) and Annex IV (Energy) to the EEA Agreement

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,

Whereas:

| (1) | Commission Regulation (EU) No 4/2014 of 6 January 2014 amending Regulation (EC) No 640/2009 implementing Directive 2005/32/EC of the European Parliament and of the Council with regard to ecodesign requirements for electric motors (1) is to be incorporated into the EEA Agreement. |
| --- | --- |

(1)

Commission Regulation (EU) No 4/2014 of 6 January 2014 amending Regulation (EC) No 640/2009 implementing Directive 2005/32/EC of the European Parliament and of the Council with regard to ecodesign requirements for electric motors (1) is to be incorporated into the EEA Agreement.

| (2) | Annexes II and IV to the EEA Agreement should therefore be amended accordingly, |
| --- | --- |

(2)

Annexes II and IV to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following is added in point 13 (Commission Regulation (EC) No 640/2009) of Chapter IV of Annex II to the EEA Agreement:

‘, as amended by:

| — | 32014 R 0004: Commission Regulation (EU) No 4/2014 of 6 January 2014 (OJ L 2, 7.1.2014, p. 1).’ |
| --- | --- |

—

32014 R 0004: Commission Regulation (EU) No 4/2014 of 6 January 2014 (OJ L 2, 7.1.2014, p. 1).’

Article 2

The following is added in point 36 (Commission Regulation (EC) No 640/2009) of Annex IV to the EEA Agreement:

‘, as amended by:

| — | 32014 R 0004: Commission Regulation (EU) No 4/2014 of 6 January 2014 (OJ L 2, 7.1.2014, p. 1).’ |
| --- | --- |

—

32014 R 0004: Commission Regulation (EU) No 4/2014 of 6 January 2014 (OJ L 2, 7.1.2014, p. 1).’

Article 3

The text of Regulation (EU) No 4/2014 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.

Article 4

This Decision shall enter into force on 17 May 2014, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).

Article 5

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.

Done at Brussels, 16 May 2014.

For the EEA Joint Committee

The President

Gianluca GRIPPA

---

(1)  
  OJ L 2, 7.1.2014, p. 1.

1

(*1)  No constitutional requirements indicated.

*1

---
<PAGE>

                                                                 EXHIBIT 10.17

                         NON-RECOURSE PROMISSORY NOTE
                         ----------------------------

$100,000                                           San Francisco, California
                                                            January 28, 2000

     For value received, the undersigned promises to pay Aeneid Corporation, a
California corporation (the "Company"), at its principal office the principal
                             -------
sum of $100,000, together with interest on the sum of the outstanding principal
balance, plus accrued but unpaid interest, at the rate of 5.73% per annum,
compounded monthly.  Such principal and interest shall be due and payable on
January 28, 2003.

     Principal and interest are payable in lawful money of the United States of
America.  AMOUNTS DUE UNDER THIS NOTE MAY BE PREPAID AT ANY TIME WITHOUT
INTEREST OR PENALTY.

     Should suit be commenced to collect any sums due under this Note, such sum
as the Court may deem reasonable shall be added hereto as attorneys' fees.  The
makers and endorsers have severally waived presentment for payment, protest,
notice of protest, and notice of nonpayment of this Note.

     This Note, which is non-recourse, is secured by a pledge of certain shares
of Common Stock of the Company owned by the undersigned and is subject to the
terms of a Pledge and Security Agreement between the undersigned and the Company
of even date herewith.

     THIS NOTE IS NON-RECOURSE TO THE UNDERSIGNED.  The Company shall look
solely to any collateral securing this Note for payment of any unpaid amounts
due under this Note, whether or not the value of such collateral is sufficient
to liquidate the entire amount due.  The Company shall have no claim against the
undersigned for payment of any amount due under this Note other than to the
extent of the interest of the undersigned in the collateral securing this Note
in accordance with the aforementioned Pledge and Security Agreement.

     In the event that any one or more provisions of this Note shall be held to
be illegal, invalid or otherwise unenforceable, the same shall not affect any
other provision of this Note, and the remaining provisions of this Note shall
remain in full force and effect.

     This Note shall be governed by, and construed in accordance with, the laws
of the State of California without regard to conflicts of laws principles.

                                     /s/ Willie Tejada
                                    ----------------------
                                    Willie Tejada
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
ACCOMPANYING FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          AUG-30-2001
<PERIOD-START>                             SEP-01-2000
<PERIOD-END>                               NOV-30-2000
<CASH>                                         164,586
<SECURITIES>                                   141,759
<RECEIVABLES>                                  212,806
<ALLOWANCES>                                   (6,343)
<INVENTORY>                                     44,176
<CURRENT-ASSETS>                               581,202
<PP&E>                                         345,881
<DEPRECIATION>                                 124,402
<TOTAL-ASSETS>                                 901,195
<CURRENT-LIABILITIES>                          339,918
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           967
<OTHER-SE>                                     508,066
<TOTAL-LIABILITY-AND-EQUITY>                   901,195
<SALES>                                        404,035
<TOTAL-REVENUES>                               404,035
<CGS>                                          342,643
<TOTAL-COSTS>                                  405,912
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             (4,129)
<INCOME-PRETAX>                                  2,252
<INCOME-TAX>                                     (676)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,576
<EPS-BASIC>                                       0.02
<EPS-DILUTED>                                     0.02


</TABLE>
Chester L. BIRD, petitioner, v. Michael PACHECO, Warden, et al.

No. 17-6612.

Supreme Court of the United States

Jan. 8, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4538 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
                                H. R. 4538

To amend title III of the Public Health Service Act to limit the orphan 
 drug exclusion under the drug discount program under section 340B of 
                              such title.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           September 26, 2019

Mr. Welch (for himself and Mr. McKinley) introduced the following bill; 
       which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
To amend title III of the Public Health Service Act to limit the orphan 
 drug exclusion under the drug discount program under section 340B of 
                              such title.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Closing Loopholes for Orphan Drugs 
Act''.

SEC. 2. LIMITING THE ORPHAN DRUG EXCLUSION UNDER 340B DRUG DISCOUNT 
              PROGRAM.

    (a) In General.--Section 340B(e) of the Public Health Service Act 
(42 U.S.C. 256b(e)) is amended by inserting before the period at the 
end the following: ``when transferred, prescribed, sold, or otherwise 
used for the rare condition or disease for which such drug is so 
designated''.
    (b) Effective Date.--The amendment made by subsection (a) shall 
apply with respect to covered outpatient drugs purchased on or after 
the date of the enactment of this Act.
                                 <all>
```
EXHIBIT 32.3



CERTIFICATION PURSUANT TO

18 U. S.
C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Dominos, Inc. (the Company) on Form 10-K for the fiscal year ended January 2, 2005, as filed with the Securities and Exchange Commission on the date hereof (the Report),
I, David A. Brandon, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C.§ 1350, adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:



| | 1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
| | -- | ---------------------------------------------------------------------------------------------------------------------------------



| | 2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  |  |                         |  | 
| |  |  |  | ----------------------- |  | 
| |  |  |  | /s/ David A. Brandon    |  | 
| |  |  |  | David A. Brandon        |  | 
| |  |  |  | Chief Executive Officer |  | 



Dated: March 10, 2005
```

[Federal Register Volume 87, Number 83 (Friday, April 29, 2022)]
[Notices]
[Pages 25499-25500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-09189]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Animal Genomics Program.
    Date: May 25, 2022.
    Time: 12:00 p.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).

[[Page 25500]]

    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, 301 
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-
4471, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Recovery Support Services for 
Individuals Treated with Medications for Opioid Use Disorder.
    Date: June 6, 2022.
    Time: 10:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Research, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: April 25, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-09189 Filed 4-28-22; 8:45 am]
BILLING CODE 4140-01-P
```
**Exhibit 31.2****CERTIFICATION OF CHIEF FINANCIAL OFFICER****PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**I, Stephen P. Slay, certify that:1. I have reviewed this quarterly report on Form 10-Q of DRI Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and we have: A) designed such disclosure controls and procedures, or caused such disclosure controlsand procedures to be designed under our supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which this report is beingprepared;  B) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controlsand procedures, as of the end of the period covered by this report based on suchevaluation; and  C) disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting.5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performing the equivalentfunctions): A) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affectthe registrant’s ability to record, process, summarize and report financial information;and  B) any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.   /s/ Stephen P. Slay Stephen P. Slay  Chief Financial Officer  November 13, 2007  A signed copy of this written statement required by Section 302 has been provided to the Companyand will be retained by the Company and furnished to the Securities and Exchange Commission or itsstaff upon request.
Shpetim KONCI, petitioner, v. UNITED STATES.

No. 17-5946.

Supreme Court of the United States

Oct. 30, 2017.

*403Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
CONSENT OF INDEPENDENT
                          CERTIFIED PUBLIC ACCOUNTANTS

Rad Source Technologies, Inc. and subsidiary
formerly Computer Vending, Inc.

We hereby consent to the use in the Form 10K-SB dated January 13, 2000 of our
report dated January 6, 2000 related to the financial statements of Rad Source
Technologies, Inc. and subsidiary, formerly Computer Vending, Inc., for the year
ended September 30, 1999, and for the period October 11, 1996 (inception) to
September 30, 1998, and for the period October 11, 1996 (inception) to September
30, 1999.


                                                     Sweeney, Gates & Co.

Fort Lauderdale, Florida
January 10, 2000


                                       35
**Exhibit
      32.1**




**CERTIFICATION
      PURSUANT TO 18 U.S.C., SEC. 1350 AS ADOPTED**


**PURSUANT
      TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**





In
      connection with the Annual Report of Tactical Air Defense Services, Inc. (the
      "Company") on Form 10-KSB for the year ended December 31, 2006 as filed with
      the
      Securities and Exchange Commission on the date hereof (the "Report"), I, Mark
      Daniels, President of the Company, certify, pursuant to 18 U.S.C. section 906
      of
      the Sarbanes-Oxley Act of 2002, that:





(1)
      The
      Report fully complies with the requirements of section 13(a) or 15(d) of the
      Securities and Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and result of operations of the Company.





Date:
                June 13, 2007
            By:
            /s/
                Mark DanielsMark
                DanielsChief
                Executive Officer and Principal Financial Officer
EXHIBIT 32.2


CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Amendment No. 1 to the Annual Report of Extreme Networks, Inc. (the “ Company ”) on Form 10-K for the fiscal year ended July 3, 2011 , as filed with the Securities and Exchange Commission on the date hereof (the “ Report ”), the undersigned, in the capacities and on the dates indicated below, each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:





|    |                                                                                                                                                
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------
|(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and




|    |                                                                                                                                                     
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------
|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.










/s/ JAMES T. JUDSONJames T. JudsonInterim Vice President and Chief Financial OfficerOctober 31, 2011





A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Gabriel RIVERA-RODRIGUEZ, petitioner, v. UNITED STATES.

No. 17-6119.

Supreme Court of the United States

Oct. 30, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the First Circuit denied.
Taylor Corey AZURE, petitioner, v. UNITED STATES.

No. 17-5466.

Supreme Court of the United States

Dec. 11, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4499 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
                                H. R. 4499

To amend the Public Health Service Act to provide that the authority of 
 the Director of the National Institute on Minority Health and Health 
Disparities to make certain research endowments applies with respect to 
 both current and former centers of excellence, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           September 26, 2019

   Ms. Barragan (for herself, Mr. Carter of Georgia, and Mr. Lewis) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
To amend the Public Health Service Act to provide that the authority of 
 the Director of the National Institute on Minority Health and Health 
Disparities to make certain research endowments applies with respect to 
 both current and former centers of excellence, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``NIMHD Research Endowment 
Revitalization Act of 2019''.

SEC. 2. RESEARCH ENDOWMENTS AT BOTH CURRENT AND FORMER CENTERS OF 
              EXCELLENCE.

    Paragraph (1) of section 464z-3(h) of the Public Health Service Act 
(42 U.S.C. 285t(h)) is amended to read as follows:
            ``(1) In general.--The Director of the Institute may carry 
        out a program to facilitate minority health disparities 
        research and other health disparities research by providing for 
        research endowments--
                    ``(A) at current or former centers of excellence 
                under section 736; and
                    ``(B) at current or former centers of excellence 
                under section 464z-4.''.
                                 <all>
```
Jerry L. WELLS, Jr., petitioner, v. UNITED STATES.

No. 17-5801.

Supreme Court of the United States

Oct. 10, 2017.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.